Reduced levels of p15INK4b, p16INK4a, p21cip1 and p27kip1 in pancreatic carcinoma
- Authors:
- Gang Li
- Yuan Ji
- Chen Liu
- JingQi Li
- YingQi Zhou
View Affiliations
Affiliations: The Third General Surgery Department, Zhanghai Hospital, Second Military Medical University, Shanghai, P.R. China, Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, P.R. China, Laboratory of Cancer Research, Tongji University School of Medicine, Shanghai, P.R. China
- Published online on: January 30, 2012 https://doi.org/10.3892/mmr.2012.771
-
Pages:
1106-1110
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
Pancreatic carcinoma is one of the leading causes of cancer mortality worldwide, although the molecular mechanisms of this disease are poorly understood. The aim of this study was to examine the expression of cyclin-dependent kinase inhibitors (CDKIs) and the epigenetic modifications in the promoters of these genes. We also evaluated the correlation between the methylation status of CDKI genes and smoking habit in clinical pancreatic carcinoma specimens. Western blotting and real-time PCR were performed to assess CDKI expression. Methylation-specific PCR was carried out to examine the methylation status of the promoters of CDKI genes. In this study, we revealed that reduced levels of the CDKI proteins, p15INK4b, p16INK4a, p21cip1 and p27kip1, are a prominent feature of pancreatic carcinoma patients. The DNA hypermethylation of the promoter was observed in 40% (2 of 5) of the p15INK4b genes, 60% (3 of 5) of the p16INK4a genes and 60% of the p21cip1 genes, which markedly correlated with their decreased mRNA expression. No hypermethylation was detected in the p27kip1 gene promoter in 5 pancreatic carcinoma patients with markedly decreased expression of p27kip1 mRNA, suggesting an alternative mechanism of p27kip in these patients. In this study, patients with a smoking habit displayed methylation of 2 CDKI genes in their pancreatic carcinoma specimens. We concluded that epigenetic modification via hypermethylation represents a critical mechanism for the inactivation of CDKI genes in pancreatic carcinoma.
View References
|
1
|
P GhadirianHT LynchD KrewskiEpidemiology
of pancreatic cancer: an overviewCancer Detect
Prev278793200310.1016/S0361-090X(03)00002-312670518
|
|
2
|
AF HezelAC KimmelmanBZ StangerN BardeesyRA
DepinhoGenetics and biology of pancreatic ductal
adenocarcinomaGenes
Dev2012181249200610.1101/gad.141560616702400
|
|
3
|
A JemalR SiegelE WardCancer statisticsCA
Cancer J Clin5871962008
|
|
4
|
SJ ElledgeJ WinstonJW HarperA question of
balance: the role of cyclin-kinase inhibitors in development and
tumorigenesisTrends Cell
Biol6388392199610.1016/0962-8924(96)10030-115157521
|
|
5
|
JW HarperGR AdamiN WeiK KeyomarsiSJ
ElledgeThe p21 Cdk-interacting protein Cip1 is a potent inhibitor
of G1 cyclin-dependent
kinasesCell75805816199310.1016/0092-8674(93)90499-G8242751
|
|
6
|
JJ TangC ShenYJ LuRequirement for
pre-existing of p21 to prevent doxorubicin-induced apoptosis
through inhibition of caspase-3 activationMol Cell
Biochem291139144200610.1007/s11010-006-9206-716909308
|
|
7
|
Y LuN YamagishiT YagiH TakebeMutated
p21(WAF1/CIP1/SDI1) lacking CDK-inhibitory activity fails to
prevent apoptosis in human colorectal carcinoma
cellsOncogene16705712199810.1038/sj.onc.12015859488034
|
|
8
|
M SerranoGJ HannonD BeachA new regulatory
motif in cell-cycle control causing specific inhibition of cyclin
D/CDK4Nature366704707199310.1038/366704a08259215
|
|
9
|
CJ SherrJM RobertsCDK inhibitors: positive
and negative regulators of G1-phase progressionGenes
Dev1315011512199910.1101/gad.13.12.150110385618
|
|
10
|
P HainautT SoussiB ShomerDatabase of p53
gene somatic mutations in human tumors and cell lines: updated
compilation and future prospectsNucleic Acids
Res25151157199710.1093/nar/25.1.1519016527
|
|
11
|
M HallG PetersGenetic alterations of
cyclins, cyclin-dependent kinases, and Cdk inhibitors in human
cancerAdv Cancer
Res6867108199610.1016/S0065-230X(08)60352-88712071
|
|
12
|
F PerroneS TabanoF Colombop15INK4b,
p14ARF, and p16INK4a inactivation in sporadic and neurofibromatosis
type 1-related malignant peripheral nerve sheath tumorsClin Cancer
Res941324138200314519636
|
|
13
|
B KlumpCJ HsiehO NehlsMethylation status
of p14ARF and p16INK4a as detected in pancreatic secretionsBr J
Cancer88217222200310.1038/sj.bjc.660073412610506
|
|
14
|
Y KuriharaK EgawaS KunimotoT TakeuchiK
NoseInduction of p16/INK4a gene expression and cellular senescence
by toyocamycinBio Pharm
Bull2512721276200210.1248/bpb.25.127212392077
|
|
15
|
B CenH LiIB WeinsteinHistidine triad
nucleotide-binding protein 1 up-regulates cellular levels of
p27KIP1 by targeting ScfSKP2 ubiquitin ligase and SrcJ Biol
Chem28452655276200919112177
|
|
16
|
AB WestG KapatosC O'FarrellN-myc regulates
parkin expressionJ Biol Chem2792889628902200415078880
|
|
17
|
JG HermanJR GraffS MyöhänenBD NelkinSB
BaylinMethylation-specific PCR: a novel PCR assay for methylation
status of CpG islandsProc Natl Acad Sci
USA939821982619968790415
|
|
18
|
K BrakensiekF LängerH KreipeU
LehmannAbsence of p21CIP1, p27KIP1 and p57KIP2 methylation in MDS
and AMLLeuk Res2913571360200515936816
|
|
19
|
G SchneiderRM SchmidGenetic alterations in
pancreatic carcinomaMol Cancer2215200310.1186/1476-4598-2-15
|
|
20
|
H WuY ChenZY WangInvolvement of p21 (waf1)
in merlin deficient sporadic vestibular
schwannomasNeuroscience170149155201020600642
|
|
21
|
Y JiSL MaYP ZhangA combined treatment
TNF-α/Gefitinib alleviates the resistance to Gefitinib in PC-9
cells with acquired resistance to GefitinibAnticancer
Drug208328372009
|
|
22
|
Z WangY LuJ TangH WangH WuThe
phosphorylation status of merlin in sporadic vestibular
SchwannomasMol Cell Biochem324201206200919142715
|
